NO964199D0 - Treatment of autoimmune disease using oral tolerance and / or type I interferon - Google Patents

Treatment of autoimmune disease using oral tolerance and / or type I interferon

Info

Publication number
NO964199D0
NO964199D0 NO964199A NO964199A NO964199D0 NO 964199 D0 NO964199 D0 NO 964199D0 NO 964199 A NO964199 A NO 964199A NO 964199 A NO964199 A NO 964199A NO 964199 D0 NO964199 D0 NO 964199D0
Authority
NO
Norway
Prior art keywords
interferon
treatment
type
autoimmune disease
oral tolerance
Prior art date
Application number
NO964199A
Other languages
Norwegian (no)
Other versions
NO964199L (en
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964199L publication Critical patent/NO964199L/en
Publication of NO964199D0 publication Critical patent/NO964199D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
NO964199A 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or type I interferon NO964199D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
NO964199L NO964199L (en) 1996-10-03
NO964199D0 true NO964199D0 (en) 1996-10-03

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964199A NO964199D0 (en) 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or type I interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (en)
JP (1) JPH09511745A (en)
AU (1) AU686797B2 (en)
BR (1) BR9507451A (en)
CA (1) CA2185353A1 (en)
HU (1) HUT74900A (en)
IL (1) IL113303A0 (en)
NO (1) NO964199D0 (en)
WO (1) WO1995027499A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
CA2275890C (en) * 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations
CA2252790A1 (en) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (sidr)
ES2382488T3 (en) 1997-03-21 2012-06-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for diseases mediated by sensitized t cells comprising an il-6 antagonist as an active ingredient
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
JP4986361B2 (en) 2000-05-24 2012-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Stroke prevention method by induction of tolerance to E-selectin
CA2511209A1 (en) * 2002-12-26 2004-07-15 Daiichi Suntory Pharma Co., Ltd. Agent for treatment of pemphigoid
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (en) * 2013-11-11 2019-10-16 キッコーマン株式会社 Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
DK0627933T3 (en) * 1992-02-28 2003-03-24 Autoimmune Inc Bystander suppression of autoimmune diseases

Also Published As

Publication number Publication date
BR9507451A (en) 1997-08-05
EP0752880A1 (en) 1997-01-15
HUT74900A (en) 1997-02-28
IL113303A0 (en) 1995-07-31
CA2185353A1 (en) 1995-10-19
AU2277695A (en) 1995-10-30
HU9602750D0 (en) 1996-11-28
AU686797B2 (en) 1998-02-12
WO1995027499A1 (en) 1995-10-19
NO964199L (en) 1996-10-03
JPH09511745A (en) 1997-11-25
EP0752880A4 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
NO933240L (en) Arrangement and preparation of toothbrush
EP0963219A4 (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
IT9083334A0 (en) PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF HUMAN GENOMIC DNA
GB9214857D0 (en) Human nucleic acid fragments and their use
HUP9902055A3 (en) Medical composition for the treatment of herpes simplex virus and other infectious diseases
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
NO964199D0 (en) Treatment of autoimmune disease using oral tolerance and / or type I interferon
NO964200D0 (en) Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines
BR9707613A (en) Mixtures free of polypholic derivatives process of preparing mixtures i and ii medications and use of mixtures
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
EP0531365A4 (en) Diagnosis and treatment of viral hepatitis
HK1026096A1 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
GB9304746D0 (en) Treatment of viral infections
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO973193D0 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
ZA939756B (en) Monocional antibodies and anti-idiotypic antibodies to hepatitits c virus
PL322002A1 (en) Variants of human dnase i
NO981719D0 (en) Use of protein S-100b in medications and medications containing protein S-100b
DE69634044D1 (en) HUMAN CYCLIN I AND THE DAFUER ENCODING GEN
ITRM940210A0 (en) PROCEDURE FOR THE PURIFICATION OF POLYCARBUNATE AND POLYESTERCARBONATE SOLUTIONS
ZA958950B (en) Treatment of hla-dr associated immunodeficiency with gamma-interferon
UA25336A (en) METHOD OF TREATMENT OF VENTURAL DISEASE OF THE REMOVAL AND DUODY
AU3163795A (en) Treatment of autoimmune diseases
GB9422923D0 (en) Treatment of viral infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application